TAK-220 a Novel Small-Molecule CCR5 Antagonist Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro

摘要

TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.